News | Cardiovascular Clinical Studies | July 15, 2022

Molecular Heart Mapping and Cripsr Technology Create New Possibilities for Health Science

MMRI Scientist Dr. Nathan Tucker co-authors groundbreaking study with team from The Broad Institute of MIT and Harvard, Bayer AG
 

MMRI Scientist Dr. Nathan Tucker co-authors groundbreaking study with team from The Broad Institute of MIT and Harvard, Bayer AG

Image courtesy of MMRI


July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details of the heart at the cellular level. What if we could zoom in even further, via single nucleus profiling, to peer inside the heart with a molecular view? Imagine the incredible possibilities of such a detailed map: With this knowledge, doctors will be better able to diagnose and treat diseases of the heart and cardiovascular system.    

This is precisely what a team of 19 scientists are determined to learn, in a new peer-reviewed study published in the science journal, Nature. The study, titled, “Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy,” identified molecular alterations in failing hearts at single-cell resolution, by performing single-nucleus RNA sequencing of nearly 600,000 nuclei. This is truly a story of how a “small view” can have “big possibilities.”   

The team was led by Patrick T. Ellinor, MD, PhD an Institute Member at the Broad Institute of MIT and Harvard and a cardiologist in the Demoulas Center for Cardiac Arrhythmias at the Massachusetts General Hospital Heart Center. Dr. Ellinor’s team included scientists from the Precision Cardiology Lab (PCL) of the Broad Institute of MIT and Harvard and Bayer, AG and MMRI.    

Dr. Nathan Tucker of Masonic Medical Research Institute was a driving force behind the initiation of the study when he was at Broad, and he continued to contribute to the study from his lab in Utica, New York. “We often think of hearts solely as muscles, but they are actually a complex mixture of cells that need to work together in order to perform its function as a pump,” said Dr. Tucker, regarding the new study. “In the past, we have not been able to look at these other critical components, but through revolutionary technology such as we use here, our ability to accurately examine these other cells is unlocked. In this study, using this technology and a series of human tissue samples, we identified novel state transitions in end stage heart failure at single cell resolution. It is our hope to use these new targets as the basis for therapeutic development in the future.”  

The ground-breaking effort builds upon Dr. Tucker’s already extensive work on heart mapping. In 2020, Dr. Tucker led a team to create a cell map of the human heart, the most comprehensive to date, stating, “Understanding of human cardiac biology at this resolution was not possible just a few years ago."  

For more information: www.MMRI.edu 


Related Content

News | Heart Failure

Oct. 22, 2025 – Ventric Health, a medtech innovator enabling early detection of heart failure (HF) in a primary care ...

Home October 28, 2025
Home
News | Heart Failure

Oct. 16, 2025 — Imbria Pharmaceuticals, has announced a partnership with the Hypertrophic Cardiomyopathy Association ...

Home October 16, 2025
Home
News | Heart Failure

Sept. 24, 2025 — The Family Heart Foundation, a leading research and advocacy organization, has announced the online ...

Home September 24, 2025
Home
News | Heart Failure

Sept. 22, 2025 — The latest findings on heart failure (HF) published by the Heart Failure Society of America (HFSA) ...

Home September 22, 2025
Home
News | Heart Failure

Sept. 11, 2025 — Newswise — A new Mayo Clinic study finds that many heart attacks in people under 65 — especially women ...

Home September 15, 2025
Home
News | Heart Failure

Aug. 14, 2025 — Analytics For Life, in collaboration with its U.S. commercial partner CorVista Health, announced they ...

Home August 15, 2025
Home
News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
Subscribe Now